The "Elevate" by MAPS Podcast

How do you deliver impactful medical education? Hear from industry experts how to design medical education programs successfully for today’s healthcare professionals, in our latest podcast episode, sponsored by Wiley.

In today's episode, we're talking with Joseph Zabinski, PhD, Senior Director, AI & Personalized Medicine at OM1 about Artificial Intelligence — specifically about how AI can accelerate diagnosis and treatment. This episode is sponsored by OM1.

Today we're talking about publications impact with Mike Taylor, Head of Data Insights and GRONYA Farrell, Manager Corporate Life Science, Central Europe, both at Digital Science. We'll discuss the questions:

1. Where are we now?
2. Are we looking beyond impact factor? 
3. And how to do we make sense of the data and translate "numbers" into "actionable insights". 

This episode is sponsored by Digital Science, choosing journals and understanding publication impact in the digital age.

Post-approval safety studies have traditionally been cumbersome and expensive, and safety study sites are likely to mirror those used in clinical trials, leading organizations to potentially miss safety signals in populations beyond those that typically participate at trial sites. Here we speak with Stefan C. Weiss, MD, Managing Director, Dermatology at OM1 about a transformation in the way we conduct safety studies — relying on EMR patient data overlain with technology to create a more accurate and equitable view of post-market safety.

As technology changes the ways we engage with external stakeholders, the skills we need to manage these interactions are changing, as well. Here we speak with Jen Millard, Vice President of Field Medical at IQVIA, about emerging competencies for external engagement. This episode is sponsored by IQVIA. 

Patient communities continue to mobilize and play an increasingly important role by influencing many elements of the drug development journey and subsequent patient access and support activities. This input ranges from natural history studies, recruitment in clinical trials, understanding burden, contributing to Health Technology Assessments and co-creating educational resources that enable shared decision making and adherence support. Given Medical Affairs stakeholders have similar reach across drug development and commercialization it is logical that this function plays a central role in an organization’s patient-first thinking and strategy. To achieve this, Medical Affairs stakeholders will need to develop thoughtful and impactful strategies that not only build the trust of patient communities but also their internal colleagues.  Here we discuss patient-centricity strategies and actions with Gavin Jones, Global Advisor Rare Disease, OPEN Health, Jenny Ghith, Senior Director, Omnichannel Strategy and Innovations Lead, Pfizer, and Brittany Wolf, Director, Patient Centricity Lead, Pfizer. 

This podcast series focuses on how digital is transforming scientific communications.  

In this, our second episode this season, we'll be discussing open access in medical publishing from the biopharma perspective.

In this Opening Doors episode of the Medical Affairs Professional Society podcast series, Elevate, we speak with Áine Prendergast, Medical Science Liaison in Oncology with Ipsen. Hear about Áine's path into the profession and learn important advice that can help you find a first MSL position.

In this second podcast in this series, we will discuss delivering constructive feedback.

On today's episode of the MAPS "Elevate" podcast, we're discussing the use of Real-World Evidence to understand and possibly intercede in treatment-resistant depression and why is it especially difficult to develop treatments against resistant depression using the traditional structure of R&D-led clinical trials.